Dr. Andrew Chadeayne<\/a>, CEO of CaaMTech. \u201cWe are eager to work with NIDA to eliminate ambiguity in psychedelic research through quantitative science with precise amounts of rigorously characterized compounds.\u201d<\/p>\n\n\n\nThe collaborative research aims to fill several gaps in the scientific understanding of synthetic tryptamine-based compounds. While some of these compounds reputedly produce psychedelic effects, in many cases the only evidence comes from anecdotal reports of people consuming questionable amounts of poorly-characterized chemicals. The full scope of pharmacological effects of many tryptamine-based compounds has never been scientifically studied. To address this problem, CaaMTech has synthesized a library of tryptamine-based compounds and determined their composition and purity using x-ray crystallography: the gold standard for chemical characterization.<\/p>\n\n\n\n
Research conducted by the DDRU at NIDA IRP will assess the pharmacological target profiles and efficacies, pharmacokinetic profiles, behavioral efficacies, and physiological effects of synthetic tryptamine-based compounds using in vitro<\/em> and in vivo<\/em> assays. CaaMTech will supply purified, crystalline tryptamine-based compounds for the research, as well as expertise, advice, and data support to complete the studies. The studies will provide much-needed data about synthetic tryptamine-based compounds and allow researchers to compare these compounds to more thoroughly-studied compounds such as psilocybin, opening the door to the development of safer, more effective psychedelic drugs.<\/p>\n\n\n\n\u201cPsilocybin is just the first of many psychedelic tryptamine-based compounds to receive meaningful scientific attention,\u201d said Dr. Chadeayne. \u201cNow that we have a library of reliable compounds, our goal is to increase the number of candidates available for clinical trials by filling in much-needed information about their pharmacological properties. We look forward to advancing the best candidates into an FDA approval process to ultimately improve the available options for treating mental health disorders.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech\u2019s library of tryptamine-based compounds<\/p>\n","protected":false},"author":1,"featured_media":235,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/234"}],"collection":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/comments?post=234"}],"version-history":[{"count":0,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/posts\/234\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/media\/235"}],"wp:attachment":[{"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/media?parent=234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/categories?post=234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/caam.tech\/wp-json\/wp\/v2\/tags?post=234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}